JP2022549344A5 - - Google Patents
Info
- Publication number
- JP2022549344A5 JP2022549344A5 JP2022519172A JP2022519172A JP2022549344A5 JP 2022549344 A5 JP2022549344 A5 JP 2022549344A5 JP 2022519172 A JP2022519172 A JP 2022519172A JP 2022519172 A JP2022519172 A JP 2022519172A JP 2022549344 A5 JP2022549344 A5 JP 2022549344A5
- Authority
- JP
- Japan
- Prior art keywords
- prodrug
- polypeptide chain
- subunit
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962907615P | 2019-09-28 | 2019-09-28 | |
| US62/907,615 | 2019-09-28 | ||
| PCT/US2020/053155 WO2021062406A1 (en) | 2019-09-28 | 2020-09-28 | Cytokine prodrugs and dual-prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022549344A JP2022549344A (ja) | 2022-11-24 |
| JP2022549344A5 true JP2022549344A5 (https=) | 2023-08-31 |
Family
ID=73131796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022519172A Pending JP2022549344A (ja) | 2019-09-28 | 2020-09-28 | サイトカインプロドラッグおよびデュアルプロドラッグ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220356221A1 (https=) |
| EP (1) | EP4034551A1 (https=) |
| JP (1) | JP2022549344A (https=) |
| CN (1) | CN114401997B (https=) |
| AU (1) | AU2020353235A1 (https=) |
| CA (1) | CA3153785A1 (https=) |
| WO (1) | WO2021062406A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CA3141626A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| CA3165927A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| JP7773991B2 (ja) * | 2020-03-23 | 2025-11-20 | ザイムワークス ビーシー インコーポレイテッド | マスクされたｉｌ１２融合タンパク質及びその使用方法 |
| JP7771076B2 (ja) * | 2020-04-01 | 2025-11-17 | エクシリオ デベロップメント， インコーポレイテッド | マスクされたｉｌ－１２サイトカイン及びその切断産物 |
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| IL298136A (en) | 2020-05-13 | 2023-01-01 | Bonum Therapeutics Inc | Preparations of protein complexes and methods of using them |
| CA3178657A1 (en) * | 2020-05-19 | 2021-11-25 | William Winston | Activatable il-12 polypeptides and methods of use thereof |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| US20240228586A1 (en) * | 2021-05-07 | 2024-07-11 | The University Of Chicago | Compositions and methods comprising protease-activated therapeutic agents |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| AU2023226005A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| CN116621965A (zh) * | 2022-05-06 | 2023-08-22 | 珠海丽凡达生物技术有限公司 | 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用 |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| US20240376170A1 (en) | 2023-01-11 | 2024-11-14 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| WO2024211877A2 (en) * | 2023-04-06 | 2024-10-10 | Werewolf Therapeutics, Inc. | Il-12 prodrugs, methods of use and pharmaceutical compositions |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| TW202523680A (zh) * | 2023-12-07 | 2025-06-16 | 大陸商上海藥明生物技術有限公司 | 針對ｉｌ－１２受體的異二聚體蛋白 |
| CN120230225A (zh) * | 2024-02-07 | 2025-07-01 | 上海交通大学 | 活性可调节的il-12融合蛋白及其用途 |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| ES2590912T3 (es) * | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
| DE10045592A1 (de) * | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| EP1702069A2 (en) * | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| KR20160116056A (ko) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-ｉｌ-12/ｉｌ-23 항체 |
| WO2012065086A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| PE20141017A1 (es) | 2011-03-02 | 2014-08-25 | Roche Glycart Ag | Anticuerpos del cea |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| WO2019129053A1 (zh) * | 2017-12-26 | 2019-07-04 | 南京金斯瑞生物科技有限公司 | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 |
| EP3762406A2 (en) * | 2018-03-09 | 2021-01-13 | Askgene Pharma, Inc. | Cytokine prodrugs |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| WO2020023702A1 (en) * | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CA3141626A1 (en) * | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| CA3165927A1 (en) * | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| WO2022155263A2 (en) * | 2021-01-12 | 2022-07-21 | Askgene Pharma Inc. | Chimeric molecules comprising il-12 agonist polypeptide |
-
2020
- 2020-09-28 AU AU2020353235A patent/AU2020353235A1/en not_active Abandoned
- 2020-09-28 CA CA3153785A patent/CA3153785A1/en active Pending
- 2020-09-28 CN CN202080064459.1A patent/CN114401997B/zh active Active
- 2020-09-28 EP EP20801423.3A patent/EP4034551A1/en active Pending
- 2020-09-28 US US17/762,864 patent/US20220356221A1/en active Pending
- 2020-09-28 JP JP2022519172A patent/JP2022549344A/ja active Pending
- 2020-09-28 WO PCT/US2020/053155 patent/WO2021062406A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022549344A5 (https=) | ||
| JP7820448B2 (ja) | 新規のサイトカインプロドラッグ | |
| US20250368730A1 (en) | Anti-mesothelin antibodies | |
| JP6827415B2 (ja) | 疾患の処置のための併用療法 | |
| CA3143995A1 (en) | Anti-tigit antibodies | |
| WO2021035188A1 (en) | Novel il-21 prodrugs and methods of use thereof | |
| WO2020238926A1 (en) | Anti-b7-h3 antibodies | |
| CN111499753B (zh) | 双功能抗体及其用途 | |
| JPWO2021177438A5 (https=) | ||
| JP2021100949A (ja) | Ｄｓｇ２モノクローナル抗体およびその応用 | |
| JP2021506748A (ja) | 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合 | |
| JP2023524678A (ja) | 抗ｃ－Ｍｅｔ抗体薬物複合体及びその応用 | |
| TW202320827A (zh) | 用於治療癌症之檢查點抑制劑和溶瘤病毒的組合 | |
| JP2023552733A (ja) | 抗クローディン－１８．２抗体及びその抗体薬物複合体 | |
| US20240082394A1 (en) | Combination therapy for the treatment of cancer | |
| EP3864039B1 (en) | Neuroendocrine cancer targeted therapy | |
| US20250388695A1 (en) | Epcam-cd3 epsilon bispecific antibodies | |
| US20240342246A1 (en) | Interleukin-12 variants and methods of use | |
| CN105828841A (zh) | 抗-efna4抗体-药物缀合物 | |
| WO2025048716A1 (en) | Anti-alpp/alppl2 antibodies, antibody-drug conjugates, and uses thereof | |
| JP2026512687A (ja) | ヒト化ｌ１ｃａｍ抗体－薬物複合体 | |
| JP2022543657A5 (https=) | ||
| EP4393515A1 (en) | Anti-cldn-18.2 antibody-drug conjugate and use thereof | |
| WO2026052074A1 (zh) | 包含抗体偶联药物和免疫检查点抑制剂的药物组合及其应用 | |
| HK40097873A (zh) | 用於治疗癌症的组合疗法 |